

**MINUTES OF FINANCIAL EVALUATION COMMITTEE MEETING FOR TENDER NO.-
BMSIC/DRUGS/25-08 (RE-TENDER FOR RATE CONTRACT AND SUPPLY OF DRUGS FOR
DIFFERENT HEALTHCARE FACILITIES OF STATE OF BIHAR).**

Date: 18th July 2025

Venue: BMSICL Conference Hall.

The **Financial Evaluation Committee Meeting** for **Tender No. BMSIC/DRUGS/25-08** was held on **18th July 2025** under the Chairmanship of **Managing Director, BMSICL**. The other committee members present in the meeting were:

1. Dr. Pramod Kumar Singh, Director in Chief, Health Department, GoB.
2. Smt. Kumari Seema, CGM (Supply Chain), BMSICL.
3. Sh. Harendra Ram, GM (Procurement), BMSICL.
4. Sh. Shrawan Kumar, Internal Financial Advisor (IFA), of Health Department, GoB.
5. Sh. Rajesh Kumar, Administrative Officer-cum-I/C Procurement, SHSB.
6. Principal, PMCH, Patna.
7. Sh. Ramendra Kumar, GM (Finance), BMSICL.

2. The Details of the invited tender are as follows:

1. Tender Reference No. BMSIC/DRUGS/25-08.
2. Tender floated date- 25/04/2025.
3. Last date of submission of online bids- 21/05/2025.

3. The Tender has been floated on e-proc2 Portal for 04 (Four) Drugs.

4. Total 02 (Two) bidders were found to have successfully submitted their bids on the e-proc2 online system. The submission status of original hard copy of Earnest Money Deposit (EMD), till the stipulated time was found as following: -

S. N.	Name of the Firm	Online submission status of bids on E-Proc2	Requisite Amount of EMD receipt Status	Remarks
1	M/s Novo Nordisk India Private Limited	Ok	Received	Ok
2	M/s Roche Products (India) Pvt. Ltd.	Ok	Received	Ok

5. The item wise bid received status was as follows:

S.N.	Name of the Drug	Participating Firms	No. of Bids
1	Glycopegylated/Pegylated Recombinant Factor VIII 500 IU Injection Vial	M/s Novo Nordisk India Private Limited	1
2	Glycopegylated/Pegylated Recombinant Factor VIII 1000 IU Injection Vial	M/s Novo Nordisk India Private Limited	1
3	Emicizumab 30mg/1ml Injection Vial	M/s Roche Products (India) Pvt. Ltd.	1
4	Emicizumab 60mg/0.4ml Injection Vial	M/s Roche Products (India) Pvt. Ltd.	1

6. The summary of Bid received status was as follows:

1. Single Bid received for **04** Drugs.

7. It was therefore unanimously decided by TEC in its meeting dated 23.05.2025 to recommend to evaluate the bids for above mentioned **04 Drugs** (NIT S.N.- 1, 2, 3 & 4), for which Single bid has been received, as per the Bihar Financial(Amendment) Rules, 2024 (this being a retender).

8. The Preliminary Evaluation of technical bids from the aforementioned bidding firms was conducted by the assigned team, including Drug Inspectors deputed at BMSICL. Evaluation sheets were published on the BMSICL website, and claims/objections were invited online vide notice no. 2532 dated 09/06/2025 on e-proc2.

9. After evaluating the clarifications received from the bidders in response to the notice and close examination of the documents submitted by the firms, the Drug wise technical evaluation findings by TEC in its meeting dated 03.07.2025 for each firm were recorded with the help of Drugs Inspectors deputed at BMSICL as follows:

S.N.	Name of the Drug	Participating Firms	Technical Qualification Status (Qualified/ Disqualified)	Remarks
1	Glycopegylated/Pegylated Recombinant Factor VIII 500 IU Injection Vial	M/s Novo Nordisk India Private Limited	Qualified	Ok
2	Glycopegylated/Pegylated Recombinant Factor VIII 1000 IU Injection Vial	M/s Novo Nordisk India Private Limited	Qualified	Ok
3	Emicizumab 30mg/1ml Injection Vial	M/s Roche Products (India) Pvt. Ltd.	Qualified	Ok
4	Emicizumab 60mg/0.4ml Injection Vial	M/s Roche Products (India) Pvt. Ltd.	Qualified	Ok

10. According to the comparative chart above, a total of two (02) firms namely, M/s Novo Nordisk India Private Limited & M/s Roche Products (India) Pvt. Ltd. were found technically qualified notwithstanding their product wise qualification status as mentioned above. Both the firms namely, M/s Novo Nordisk India Private Limited & M/s Roche Products (India) Pvt. Ltd. are importers.

11. It was therefore unanimously decided by TEC in its meeting dated 03.07.2025 to recommend for opening of the financial bids of the technically qualified bidders on e-proc2 portal.

12. Accordingly, the financial bids of technically qualified bidders were opened today on e-proc2 portal, in which the following result has been observed: -

S.N.	Name of the Drug	Participating Firms	Quoted Rate (Rs.) for Each Unit (per Vial) (Excluding GST)	Bid Ranking
1	Glycopegylated/Pegylated Recombinant Factor VIII 500 IU Injection Vial	M/s Novo Nordisk India Private Limited	6990	L1
2	Glycopegylated/Pegylated Recombinant Factor VIII 1000 IU Injection Vial	M/s Novo Nordisk India Private Limited	13980	L1
3	Emicizumab 30mg/1ml Injection Vial	M/s Roche Products (India) Pvt. Ltd.	39723	L1
4	Emicizumab 60mg/0.4ml Injection Vial	M/s Roche Products (India) Pvt. Ltd.	79246	L1

13. Since this tender is a retender, it was unanimously decided to ask the bidders for the above-mentioned **04 drugs** (NIT S.N.- 1, 2, 3 & 4) under single bid condition to justify their quoted price vis-à-vis other procurement agencies across the country and to find out the prevailing market rate (Authorized dealer price, Carrying & Forwarding Agent Price & Sales depot price) of the corresponding manufacturer through the State Drug Regulatory Authority, so that the matter could be decided by the board of Directors of BMSICL as per the Bihar Financial(Amendment) Rules, 2024.

14. The meeting thus concluded with a vote of thanks.

Sd/-
(Ramendra Kumar)
GM (Finance), BMSICL, Patna.

Sd/-
Principal, PMCH, Patna.

Sd/-
(Rajesh Kumar)
Administrative Officer-cum-I/C Procurement,
SHSB.

Sd/-
(Shrawan Kumar)
Internal Financial Advisor, Health Dept., Govt. of
Bihar.

Sd/-
(Harendra Ram)
GM (Procurement), BMSICL, Patna.

Sd/-
(Kumari Seema)
CGM (Supply Chain), BMSICL, Patna.

Sd/-
(Dr. Pramod Kumar Singh)
Director in Chief, Health Dept., Govt. of Bihar.

Sd/-
(Dr. Nilesh Ramchandra Deore)
Managing Director, BMSICL.